ABSTRACT
First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms (DMM), helping early-career researchers promote themselves alongside their papers. Phillipe O'Brien, Kai Guo, Stephanie Eid, Amy Rumora and Lucy Hinder are first authors on ‘Integrated lipidomic and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and type 2 diabetes’, published in DMM. Phillipe, Stephanie, Amy and Lucy are all postdoctoral researchers in the lab of Eva L. Feldman at the University of Michigan, MI, USA, investigating the pathogenesis of peripheral neuropathy using mouse models of obesity and diabetes. Kai is a postdoctoral researcher in the lab of Junguk Hur at the University of North Dakota, Grand Forks, ND, USA, and uses high-throughput genomic data analysis to understand the development of neurological disorders.
Left to right: Stephanie Eid, Phillipe O'Brien and Amy Rumora
How would you explain the main findings of your paper to non-scientific family and friends?
Obesity and diabetes are associated with the development of peripheral nerve damage, termed neuropathy. It is accepted that a diet rich in fat leads to nerve dysfunction in mouse models of obesity and diabetes. We have shown that switching the diet in mice from a high-fat to a normal diet, a form of lifestyle intervention, improves metabolic health and nerve function. Using this system of dietary reversal, our objective in this study was to explore the contribution of lipids to nerve damage. We found that levels of a specific class of lipids, triglycerides, and a protein involved in triglyceride synthesis, DGAT2, were elevated in the nerves of mice fed a high-fat diet but decreased in mice with dietary reversal. This study highlights that abnormal nerve lipid levels, as well as the type of lipids, contribute to nerve injury in obesity and diabetes.
“This study highlights that abnormal nerve lipid levels, as well as the type of lipids, contribute to nerve injury in obesity and diabetes.”
What are the potential implications of these results for your field of research?
Peripheral neuropathy is a common complication of obesity and type 2 diabetes that substantially impacts the patient's quality of life. Currently, there is no effective treatment and management. In patients with prediabetes and diabetes – common causes of peripheral neuropathy – management consists of tight glycemic control, which does not prevent peripheral neuropathy development. Thus, identifying the drivers of disease is important to develop therapeutic strategies. In this study, we demonstrate that nerve lipids, particularly triglycerides, are implicated in peripheral neuropathy, reinforcing the hypothesis that lipids are important factors in the onset and progression of neuropathy. Therefore, current research efforts should focus on identifying the mechanisms by which dietary lipids lead to nerve dysfunction.
What are the main advantages and drawbacks of the model system you have used as it relates to the disease you are investigating?
One of the main advantages of the high-fat-diet-fed mouse model is that, unlike the genetically modified db/db and ob/ob mouse models, these mice develop a gradual onset of disease, while retaining functional leptin signaling. Importantly, they consistently develop a robust peripheral neuropathy that mimics the human condition.
Another advantage of using this mouse model is that disease onset is inducible rather than spontaneous, which allows investigators to study disease onset and progression at different ages and stages.
A limitation of the high-fat-diet mouse model is that there is no consensus among research teams on the protocol for generating this model. These include: genetic background, strain, vendors of mice and diet, animal age, duration of high-fat feeding, percentage of fat, and diet composition. For this reason, agreeing on a common protocol is important to move the research forward.
“Another advantage of using this mouse model is that disease onset is inducible rather than spontaneous, which allows investigators to study disease onset and progression at different ages and stages.”
What has surprised you the most while conducting your research?
Although there is no pharmacological intervention for peripheral neuropathy, our findings once again show that lifestyle intervention through dietary reversal can improve nerve function in obesity and type 2 diabetes. Our results also highlight the role of nerve triglycerides in neuropathy, which can be reversed via dietary intervention.
Describe what you think is the most significant challenge impacting your research at this time and how will this be addressed over the next 10 years?
Type 2 diabetes and peripheral neuropathy are complex and multifactorial disorders, with both genetics and environment contributing to disease pathogenesis. Although the high-fat-fed mouse model serves as a robust animal model that recapitulates the human condition, the most significant challenge is establishing a unified approach across research groups. Ideally, over the next 10 years, a framework should be set into place with clearly defined protocols to overcome the current limitations.
“The lack of NIH funding opportunities is a major challenge faced by international postdoctoral fellows, which hinders career advancement.”
What changes do you think could improve the professional lives of early-career scientists?
The lack of NIH funding opportunities is a major challenge faced by international postdoctoral fellows, which hinders career advancement. Additionally, improved training opportunities in grant writing would be beneficial for early-career investigators. A standardized framework for training in grant writing would be helpful to ensure that all postdoctoral fellows have the resources they need to launch an independent scientific career.
What's next for you?
In the current study, we found that triglycerides and DGAT2, an enzyme that catalyzes the final step in triglyceride synthesis, are implicated in peripheral neuropathy. The next step would be to investigate the factors that regulate nerve triglycerides, with major emphasis on the role of DGAT2. These studies will confirm whether targeting triglycerides, or triglyceride synthesis pathways, will provide therapeutic benefit against peripheral neuropathy.
Footnotes
Phillipe O'Brien, Stephanie Eid, Amy Rumora and Lucy Hinder's contact details: University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA. Kai Guo's contact details: University of North Dakota, Grand Forks, ND 58202-9037, USA.
E-mail: philobri{at}med.umich.edu; kai.guo{at}und.edu; steid{at}med.umich.edu; arumora{at}med.umich.edu; lucyhind{at}med.umich.edu
- © 2020. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Reference
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief
We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’
Did you know DMM Conference Travel Grants can be used for online meetings?
With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.
The current application round closes on 8 February 2021 – find out more.
Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart
Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.
C. elegans as a disease model
A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.
Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.
Interview – Kim Landry-Truchon and Nicolas Houde
In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.